Drug intelligence / Profile preview

BV-A829

Development stage: Preclinical
Lead developer: BioViva
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intranasal, Intravenous

Overview

BV-A829 is a preclinical gene therapy candidate developed by BioViva. The asset was identified in the company's early development pipeline, which focuses on addressing cellular aging and age-related pathologies through gene delivery. While the specific genetic cargo and therapeutic indication for BV-A829 have not been publicly disclosed, BioViva's platform typically utilizes viral vectors, such as adeno-associated virus (AAV) or cytomegalovirus (CMV), to deliver longevity-associated genes. BV-A829 represents one of the company's early-stage efforts in the field of regenerative medicine and life extension.

Other names: BV-A829BV-A-829BV-A 829

Targets

Neuraminidase

Beyond the preview

Go deeper on BV-A829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BV-A829.

Explore the full profile